Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade B 3.4 1.49% 0.05
ABUS closed up 1.49 percent on Friday, April 28, 2017, on 72 percent of normal volume.

Earnings due: May 3

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ABUS trend table...

Date Alert Name Type % Chg
Apr 28 Bollinger Band Squeeze Range Contraction 0.00%
Apr 27 Hammer Candlestick Bullish 1.49%
Apr 27 Doji - Bullish? Reversal 1.49%
Apr 27 Bollinger Band Squeeze Range Contraction 1.49%
Apr 27 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.49%
Apr 26 Hammer Candlestick Bullish 1.49%
Apr 26 Doji - Bullish? Reversal 1.49%
Apr 26 Bollinger Band Squeeze Range Contraction 1.49%
Apr 25 Bollinger Band Squeeze Range Contraction 1.49%
Apr 24 Bollinger Band Squeeze Range Contraction 3.03%

Older signals for ABUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company’s products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.9
52 Week Low 2.35
Average Volume 214,722
200-Day Moving Average 3.1839
50-Day Moving Average 3.0556
20-Day Moving Average 3.3075
10-Day Moving Average 3.335
Average True Range 0.1448
ADX 22.88
+DI 17.65
-DI: 9.31
Chandelier Exit (Long, 3 ATRs) 3.0456
Chandelier Exit (Short, 3 ATRs) 3.3844
Upper Bollinger Band 3.3867
Lower Bollinger Band 3.2283
Percent B (%b) 1.08
Bandwidth 0.047891